Trevi Therapeutics (TRVI)
(Delayed Data from NSDQ)
$2.54 USD
-0.11 (-4.15%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $2.55 +0.01 (0.39%) 5:12 PM ET
2-Buy of 5 2
D Value F Growth F Momentum F VGM
Trevi Therapeutics, Inc. (TRVI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.40 | $9.00 | $6.00 | 179.25% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Trevi Therapeutics, Inc. comes to $7.40. The forecasts range from a low of $6.00 to a high of $9.00. The average price target represents an increase of 179.25% from the last closing price of $2.65.
Analyst Price Targets (5 )
Broker Rating
Trevi Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.20 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, four are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 80% and 20% of all recommendations. A month ago, Strong Buy made up 80%, while Buy represented 20%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/1/2024 | B. Riley Securities | Mayank Mamtani | Strong Buy | Strong Buy |
2/1/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
11/9/2023 | SVB Securities | Thomas J Smith | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.20 |
ABR (Last week) | 1.20 |
# of Recs in ABR | 5 |
Average Target Price | $7.40 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 69 of 252 |
Current Quarter EPS Est: | -0.09 |